



Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

Emma J. Groen¹ · Jan Hudecek² · Lennart Mulder³ · Maartje van Seijen³ · Mathilde M. Almekinders³ · Stoyan Alexov⁴ · Anikó Kovács⁵ · Ales Ryska⁶ · Zsuzsanna Varga⁷ · Francisco-Javier Andreu Navarro⁸ · Simonetta Bianchi⁹ · Willem Vreuls¹⁰ · Eva Balslev¹¹ · Max V. Boot¹² · Janina Kulka¹³ · Ewa Chmielik¹⁴ · Ellis Barbé¹² · Mathilda J. de Rooij¹⁵ · Winand Vos¹⁶ · Andrea Farkas¹⁷ · Natalja E. Leeuwis-Fedorovich¹⁸ · Peter Regitnig¹⁹ · Pieter J. Westenend²⁰ · Loes F. S. Kooreman²¹ · Cecily Quinn²² · Giuseppe Floris^{23,24} · Gábor Cserni^{25,26} · Paul J. van Diest²⁷ · Esther H. Lips³ · Michael Schaapveld²⁸ · Jelle Wesseling^{1,3}  on behalf of Grand Challenge PRECISION consortium

Received: 25 April 2020 / Accepted: 17 July 2020
© The Author(s) 2020

Abstract

Purpose For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater reliability of histopathological DCIS features and assessed their associations with subsequent ipsilateral invasive breast cancer (iIBC) risk.

Methods Using a case-cohort design, reliability was assessed in a population-based, nationwide cohort of 2767 women with screen-detected DCIS diagnosed between 1993 and 2004, treated by breast-conserving surgery with/without radiotherapy (BCS ± RT) using Krippendorff's alpha (KA) and Gwet's AC2 (GAC2). Thirty-eight raters scored histopathological DCIS features including grade (2-tiered and 3-tiered), growth pattern, mitotic activity, periductal fibrosis, and lymphocytic infiltrate in 342 women. Using majority opinion-based scores for each feature, their association with subsequent iIBC risk was assessed using Cox regression.

Results Interrater reliability of grade using various classifications was fair to moderate, and only substantial for grade 1 versus 2 + 3 when using GAC2 (0.78). Reliability for growth pattern (KA 0.44, GAC2 0.78), calcifications (KA 0.49, GAC2 0.70) and necrosis (KA 0.47, GAC2 0.70) was moderate using KA and substantial using GAC2; for (type of) periductal fibrosis and lymphocytic infiltrate fair to moderate estimates were found and for mitotic activity reliability was substantial using GAC2 (0.70). Only in patients treated with BCS-RT, high mitotic activity was associated with a higher iIBC risk in univariable analysis (Hazard Ratio (HR) 2.53, 95% Confidence Interval (95% CI) 1.05–6.11); grade 3 versus 1 + 2 (HR 2.64, 95% CI 1.35–5.14) and a cribriform/solid versus flat epithelial atypia/clinging/(micro)papillary growth pattern (HR 3.70, 95% CI 1.34–10.23) were independently associated with a higher iIBC risk.

Conclusions Using majority opinion-based scores, DCIS grade, growth pattern, and mitotic activity are associated with iIBC risk in patients treated with BCS-RT, but interrater variability is substantial. Semi-quantitative grading, incorporating and separately evaluating nuclear pleomorphism, growth pattern, and mitotic activity, may improve the reliability and prognostic value of these features.

Keywords Ductal carcinoma in situ · Invasive breast cancer · Interrater reliability · Risk stratification

Michael Schaapveld and Jelle Wesseling: joint last authors.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10549-020-05816-x>) contains supplementary material, which is available to authorized users.

✉ Jelle Wesseling
j.wesseling@nki.nl

Extended author information available on the last page of the article

Abbreviations

DCIS	Ductal carcinoma in situ
IBC	Invasive breast cancer
iIBC	Ipsilateral invasive breast cancer
95% CI	95% Confidence Interval
BCS ± RT	Breast-conserving surgery with or without radiotherapy
NCR	Netherlands Cancer Registry

PALGA	The nationwide network and registry of histology and cytopathology in the Netherlands.
KA	Krippendorff's alpha
GAC2	Gwet's AC2
PHA	Proportional hazard assumptions
HR	Hazard Ratio
FEA	Flat epithelial atypia
HER2	Human epidermal growth factor receptor 2
ER	Estrogen receptor

Background

Ductal carcinoma in situ (DCIS) of the breast is a non-obligate precursor of invasive breast cancer (IBC). Since the introduction of organized population-based breast screening, the incidence of DCIS has increased manyfold [1–3]. Although DCIS is almost always treated to avoid progression to IBC, this has not led to a reduced IBC incidence. Breast screening programs are therefore criticized by some for being associated with overdiagnosis and overtreatment of DCIS [4–6]. It has been reported that a large proportion of untreated DCIS will not progress to IBC [7, 8]. Ryser et al. reported a 10-year net risk of ipsilateral IBC (iIBC) of 12.2% (95% Confidence Interval (95% CI) 8.6–17.1%) for women with DCIS grade 1/2 and 17.6% (95% CI 12.1–25.2%) for grade 3 [8]. Although based on selected patients, these results underline that at least some DCIS lesions have a low risk of progression and may thus be overtreated. However, reliably distinguishing high- from low-risk DCIS to guide treatment is still challenging.

Many studies have tried to find histopathological markers that could predict progression of DCIS [9, 10]. So far, no single marker ended up being used in clinical practice due to lack of conclusive evidence of predictive ability, in part due to suboptimal biased study designs in particular due to insufficient handling of confounders and poorly described study groups [10]. Especially grade has been extensively studied as a biomarker for the invasive potential of DCIS. The use of many different grading systems with partly unclear criteria and often only poor to modest interrater reliability makes it difficult to evaluate the role of grade in risk stratification [11–21].

In addition, various studies have assessed reproducibility of histopathological evaluation of DCIS lesions. Unfortunately, these studies were frequently based on highly selected case sets, assessed by expert breast pathologists often after having received instructions or tutorials beforehand and using reference diagnoses without follow-up data [17, 18, 22–28]. The interpretation of results and evaluation of potential bias is further complicated by inadequate reporting [29].

This study assesses the interrater reliability of various histopathological features in DCIS in a setting which as closely as possible reflects daily practice. We subsequently evaluate whether these features, based on a more robust majority opinion of 38 raters, are associated with risk of development of subsequent iIBC.

Methods

Patient selection


We assembled a population-based, nationwide cohort of screen-detected primary and pure DCIS, treated with breast-conserving surgery with or without adjuvant radiotherapy (BCS ± RT) between January 1, 1993 and December 31, 2004, by linkage of data from the Netherlands Cancer Registry (NCR) with data from the Dutch breast cancer screening program [30]. From 1989, the Dutch biennial screening program was gradually introduced, inviting women aged 50–69 years and from 1998 aged 50–75 years. Screen-detected DCIS was defined as DCIS detected within 30 months after a first or subsequent positive screening examination. The cohort was supplemented with data from the nationwide network and registry of histology and cytopathology in the Netherlands (PALGA) [31]. Information on age and date at diagnosis, treatment, and if applicable subsequent iIBC and vital status was provided by the NCR (follow-up data available until January 1, 2011). Patients diagnosed with a prior malignancy, other than non-melanoma skin cancer, were excluded. The review boards of the NCR, PALGA and the Dutch breast cancer screening organization approved this study.

Interrater reliability analysis

We first assessed the interrater reliability of histopathological DCIS features in this cohort using a case-cohort design [32]. From the cohort of 2767 women, we randomly sampled 357 women (subcohort; 13%) and additionally selected all 177 patients who subsequently developed an iIBC but were not included in the random sample for a total of 534 patients. Figure 1 shows the selection of patients with exclusions at pathology report review ($n=27$) and slide review ($n=76$). Slide review was based on freshly cut slides stained with hematoxylin and eosin and in case of uncertainty about the in situ nature of the lesion also with cytokeratin 14 by EJG (clone LL002; 1/3200 dilution, 32 min at 37 °C + amplification, Neomarkers/Thermo Scientific).

For 353 patients the diagnosis of pure DCIS could be confirmed and from each lesion a single slide was selected with the highest quantity of DCIS. These slides were digitized using an Aperio AT2 scanner (Leica Biosystems) at

Fig. 1 Flow diagram for patient selection and exclusions. *Subcohort* randomly selected patient group; *outside subcohort* patients who developed subsequent ipsilateral invasive breast cancer not included in the subcohort, *iIBC* ipsilateral invasive breast cancer; ^a2 outside subcohort patients developed invasive breast cancer after a mastectomy was performed during follow-up, for other reasons than *iIBC*.



20× magnification and uploaded on an online viewing platform (<https://www.slidescore.com/>). For each DCIS lesion a scoring form (see Supplementary methods) was built-in with the items: DCIS present (yes or no), grade (1, 2, or 3), grade (low or high), growth pattern (flat epithelial atypia (FEA), clinging, (micro)papillary, cribriform, or solid) and

mitotic activity of DCIS (sparse or many mitoses), calcifications (present or absent), necrosis (present or absent), periductal fibrosis (absent, subtle, or prominent) and lymphocytic infiltrate (absent, subtle, or prominent). For each item, a 'not assessable' category was also provided. Regarding DCIS growth patterns, there is controversy about whether to

consider FEA as a subtype of DCIS (clinging, monomorphic type) or not; therefore, this option was included as possible DCIS growth pattern.

European raters with varying expertise were invited to participate in the study. Each rater was assigned a study set of 146 cases to score independently, blinded to subject information. Raters were not given instructions regarding the (interpretation of) histopathological features and were requested to score as they would in daily practice to provide an unbiased baseline measure of reliability. Further details on rater selection, participation, and the scoring process are described in Supplementary methods.

Statistical analysis

In total, 11 patients were excluded from reliability analysis because > 50% of raters considered their lesion as no DCIS/not assessable (often considering atypical ductal hyperplasia/FEA as alternative diagnosis; $n = 5$) or > 25% commented on suboptimal slide quality ($n = 6$). If DCIS was not confirmed, any scores for following histopathological features were ignored. Scores for type of fibrosis were only considered when periductal fibrosis was present according to the majority opinion. Raters were excluded for the analysis of single histopathological features when they scored an item as ‘not assessable’ in > 50% of their study set.

Krippendorff’s alpha (KA), Gwet’s AC2 (GAC2), and percentage agreement were calculated to assess interrater reliability (‘not assessable’ scores were excluded) [33, 34]. KA and GAC2 are applicable to studies involving nominal/ordinal data and multiple raters scoring different subsets. A weighted analysis using linear weights was used for ordinal variables with > 2 categories. Interpretation was performed according to Landis and Koch [35]. Recategorization of grade, periductal fibrosis, and lymphocytic infiltrate was undertaken during analysis to evaluate reliability using different cut-offs.

For the analysis of subsequent iIBC risk, an additional 10 patients were excluded, because > 25% of the raters considered an invasive carcinoma component (mainly micro-invasion) to be present adjacent to DCIS ($n = 8$) or because the patient underwent a mastectomy before developing iIBC ($n = 2$). For a detailed comparison of clinical characteristics between in- versus excluded patients see Supplementary Table S1.

Associations of histopathological features, treatment, age at diagnosis, and period of diagnosis (1993–1998, reflecting the screening implementation phase, versus 1999–2004, reflecting full nationwide coverage) with risk of iIBC was assessed using Cox models. Analyses were performed irrespective of treatment as well as separately for BCS alone and BCS + RT. Interactions with treatment were also considered. Proportional hazard assumptions (PHA) were tested using

residual-based and graphical methods. In case the PHA was violated, a time factor was added, and the associations were estimated for different time-periods (i.e., for the first 5 years and after 5 years). For the histopathological features the majority opinion, i.e., the most frequently assigned category, was used in the analysis (‘not assessable’ scores were excluded). In case of equal frequencies, the presence of a histopathological feature was chosen over absence, the highest grade, the most complex growth pattern (i.e., cribriform/solid), many over sparse mitoses, prominent over subtle presence for periductal fibrosis and lymphocytic infiltrate and the least common type of fibrosis (i.e., myxoid). Time to iIBC was compared between women with low-grade DCIS versus high-grade DCIS and women treated with BCS + RT versus BCS alone using median test. Clinicopathological factors were entered in multivariable models including treatment, based on a P value ≤ 0.15 in univariable analyses. Barlow’s inverse probability weights were used to adjust the partial likelihood function for case-cohort analysis with robust variance estimation [32]. Fit of non-nested models was compared using Akaike’s and Bayesian information criteria. Two-sided P values ≤ 0.05 were considered statistically significant. All statistical analyses were performed using Stata/SE (version 13.1, Statacorp).

Results

Interrater reliability

The mean number of scores per slide was 14 (range 12–15) (Supplementary Table S2). The raters consisted of a mixed group (Supplementary Table S3), about half of them working in the Netherlands and half in other European countries within a wide range of laboratories regarding size and degree of specialization. Forty-seven percent of raters were members of the European Working Group of Breast Screening Pathologists. The diagnosis of DCIS was confirmed in 98.6% of the patients based on the majority opinion.

The interrater reliability for the 3-tiered grading system (grade 1, 2, or 3), the most commonly used histopathological feature, was only fair (KA 0.34; 95% CI 0.30–0.39) to moderate (GAC2 0.52; 95% CI 0.50–0.55; Table 1). Using a 2-tiered grading system (either low versus high grade or grade 1 + 2 versus grade 3) did not improve reliability. When the 3-tiered grading was recategorized into a category for grade 1 and a category for grade 2 + 3 combined, the reliability was substantial using GAC2 (0.78; 95% CI 0.74–0.82).

Comparable moderate (KA) to substantial (GAC2) reliability was found for growth pattern, necrosis, and calcifications, which are all features assessed in daily practice within the context of DCIS. FEA was scored 38 times in 24 different patients (representing 0.76% of all evaluations); in

Table 1 Agreement, Gwet's AC2 (GAC2), and Krippendorff's alpha (KA) coefficients per histopathological feature

Histopathological feature	Agreement (%)	95% CI (%)	GAC2	95% CI	KA	95% CI
Grade (1, 2 or 3)	76.4	75.27–77.52	0.52	0.50–0.55	0.34	0.30–0.39
Grade (1 versus 2+3)	83.5	81.33–85.68	0.78	0.74–0.82	0.35	0.28–0.42
Grade (1+2 versus 3)	69.3	66.94–71.63	0.43	0.38–0.49	0.34	0.29–0.38
Grade (low versus high)	72.8	70.54–75.12	0.52	0.47–0.57	0.38	0.32–0.44
Dominant growth pattern	84.8	82.58–86.97	0.78	0.75–0.82	0.44	0.37–0.51
Calcifications	81.1	78.81–83.40	0.70	0.65–0.75	0.49	0.43–0.54
Necrosis	81.4	79.12–83.64	0.70	0.66–0.75	0.47	0.41–0.53
Mitotic activity	78.5	76.12–80.97	0.70	0.65–0.74	0.24	0.19–0.29
Periductal fibrosis (absent, subtle or prominent presence)	70.9	69.71–72.13	0.37	0.34–0.39	0.25	0.22–0.29
Periductal fibrosis (present versus absent)	71.2	68.82–73.48	0.53	0.48–0.58	0.23	0.18–0.28
Type of periductal fibrosis (if present)	70.5	67.57–73.37	0.50	0.44–0.57	0.26	0.21–0.31
Lymphocytic infiltrate (absent, subtle or prominent presence)	77.1	75.82–78.36	0.50	0.47–0.53	0.42	0.38–0.47
Lymphocytic infiltrate (present versus absent)	73.0	70.51–75.40	0.51	0.45–0.56	0.38	0.33–0.43

GAC2 Gwet's AC2, KA Krippendorff's alpha, weighted analysis was performed for ordinal features with more than 2 categories using linear weights (grade 1–3, periductal fibrosis, and lymphocytic infiltrate), CI confidence interval

only 1 patient FEA was the majority opinion. Reliability did not change when FEA scores were excluded from analysis. A striking discrepancy in reliability was found for the assessment of mitotic activity with only fair reliability when considering KA (0.24) but substantial reliability based on GAC2 (0.70). In a 3-tiered system (absent, subtle, or prominent presence), lymphocytic infiltrate showed moderate reliability, which was slightly better than the interrater reliability for periductal fibrosis. Recategorization, comparing periductal fibrosis presence with absence led to a moderate reliability (GAC2 0.53).

Risk of subsequent iIBC after DCIS

Subcohort patients were diagnosed with DCIS at a median age of 58.4 (interquartile range 53.4–64.0) and treated by BCS alone in 40.5% (87 patients) and by BCS + RT in 59.5% (128 patients). After a median follow-up of 11.2 years (interquartile range 8.6–14.1), 20 patients developed an iIBC in the subcohort. DCIS was assigned grade 1 in 10.7%, grade 2 in 53.5%, and grade 3 in 35.8%, based on the majority opinion. Median time to iIBC was 5.3 years (interquartile range 3.3–7.6 years). Time to subsequent iIBC for women with low-grade DCIS did not differ significantly from those with high-grade DCIS (median 5.3 years versus 5.6 years, respectively, $P=0.57$). Time to iIBC for women treated with BCS + RT (median 5.9 years) did also not differ significantly from those treated with BCS alone (median 5.1 years); $P=0.12$). Table 2 shows clinicopathological characteristics of the subcohort and of all patients who developed an iIBC and Fig. 2 depicts photomicrographs of several histopathological DCIS features based on the majority opinion.

In univariable analysis, patients treated with BCS alone had a much higher risk of iIBC than patients treated with BCS + RT with a Hazard Ratio (HR) of 4.80 (95% CI 2.49–9.24) in the first 5 years and a HR of 2.47 after 5 years (95% CI 1.42–4.30; Supplementary Table S4). In patients treated with BCS alone, grade 3 (versus grade 1 + 2 combined), a cribriform/solid growth pattern (versus FEA, clinging, and (micro)papillary growth pattern), and mitotically active DCIS (versus DCIS with low mitotic activity) were also associated with a higher iIBC risk, whereas in patients treated with BCS + RT these associations were not found. In univariable analysis, a significant interaction with treatment was found for grade 3 versus 1 + 2 ($P=0.028$) and for growth pattern ($P=0.023$).

In multivariable analysis, a model which, besides treatment, included grade 3 versus grade 1 + 2 and growth pattern (cribriform and solid versus FEA, clinging, and (micro)papillary) best predicted the risk of developing iIBC in patients treated with BCS alone, while grade and growth pattern were not associated with iIBC risk in patients treated with BCS + RT (Table 3). The risk of developing iIBC did not differ between patients with DCIS grade 1/2 and FEA, clinging, or (micro)papillary growth pattern who were treated with BCS alone or BCS + RT. Figure 3 shows cumulative risk of iIBC based on categories derived from this model.

Discussion

To the best of our knowledge, this is the first study combining a comprehensive interrater reliability study in DCIS, reflecting daily practice as closely as possible, with an analysis of iIBC risk based on the majority opinion of

Table 2 Clinical characteristics and histopathological characteristics (based on the majority opinion) of the study population

Number of DCIS patients (%)	All patients with iIBC 137*	Subcohort 215**
Treatment		
BCS + RT	42 (30.7)	128 (59.5)
BCS alone	95 (69.3)	87 (40.5)
Age at DCIS diagnosis, years, median (iqr)	57.5 (53.1–63.6)	58.4 (53.4–64.0)
Age at DCIS diagnosis, years (quartiles)		
≥ 49.5—≤ 53.4	37 (27.0)	54 (25.1)
> 53.4—≤ 58.2	36 (26.3)	50 (23.3)
> 58.2—≤ 63.8	32 (23.4)	56 (26.1)
> 63.8—≤ 75.6	32 (23.4)	55 (25.6)
Period of DCIS diagnosis ^a		
1993—1998	76 (55.5)	82 (38.1)
1999—2004	61 (44.5)	133 (61.9)
Median follow-up, years (iqr)		11.2 (8.6–14.1)
Time to iIBC, years, median (iqr)	5.3 (3.3–7.6)	
Grade (1,2 or 3)		
Grade 1	10 (7.3)	23 (10.7)
Grade 2	67 (48.9)	115 (53.5)
Grade 3	60 (43.8)	77 (35.8)
Grade (low versus high)		
Low grade	31 (22.6)	60 (27.9)
High grade	106 (77.4)	155 (72.1)
Dominant growth pattern ^b		
FEA, clinging, (micro)papillary	14 (10.2)	34 (15.9)
Cribriform, solid	123 (89.8)	180 (84.1)
Calcifications		
Present	103 (75.2)	168 (78.1)
Absent	34 (24.8)	47 (21.9)
Necrosis		
Present	109 (79.6)	167 (77.7)
Absent	28 (20.4)	48 (22.3)
Mitoses		
Sparse	114 (83.2)	198 (92.1)
Many	23 (16.8)	17 (7.9)
Periductal fibrosis		
Absent	28 (20.4)	41 (19.1)
Subtle	73 (53.4)	102 (47.4)
Prominent	36 (26.3)	72 (33.5)
Type of periductal fibrosis ^c		
Sclerotic	80 (73.4)	133 (76.4)
Myxoid	29 (26.6)	41 (23.6)
Lymphocytic infiltrate		
Absent	38 (27.7)	77 (35.8)
Subtle	65 (47.5)	89 (41.4)
Prominent	34 (24.8)	49 (22.8)

subcohort randomly selected patient group, *iqr* interquartile range

*Six out of all patients with iIBC developed breast cancer metastases only


**Sixteen patients from the subcohort developed an iIBC and four developed breast cancer metastases only

^a1993–1998 reflecting part of the screening implementation phase and 1999–2004 reflecting full nationwide coverage

^bIn one patient, growth pattern was scored as not assessable by all raters and was therefore excluded (n included patients = 331); FEA = flat epithelial atypia

^cFor type of fibrosis, patients were only included when according to the majority opinion periductal fibrosis was present, either subtle or prominent (n included patients = 268)

Fig. 2 Photomicrographs from histopathological DCIS features based on the majority opinion. **a** low-grade DCIS (hematoxylin and eosin (H&E); $\times 200$), **b** high-grade DCIS (H&E; $\times 200$), **c** many mitoses (H&E; $\times 200$), **d** necrosis (H&E; $\times 200$), **e** subtle periductal fibrosis (H&E; $\times 50$), **f** prominent periductal fibrosis (H&E; $\times 50$), **g** sclerotic periductal fibrosis (H&E; $\times 50$), **h** myxoid periductal fibrosis (H&E; $\times 50$), **i** subtle periductal lymphocytic infiltrate (H&E; $\times 50$), **j** prominent periductal lymphocytic infiltrate (H&E; $\times 50$)



a large group of raters. This approach minimizes the muddling effect of interrater variability and subjectivity on the evaluation of the prognostic value of histopathological features. It will improve our ability to identify those


histopathological DCIS features that matter the most in terms of iIBC risk, on which future studies which aim to optimize reliability should focus.

Table 3 Associations of histopathological features with subsequent iIBC in multivariable analysis

Histopathological feature	BCS alone			BCS + RT			Treatment interaction <i>P</i>
	<i>n</i>	HR (95% CI)	<i>P</i>	<i>n</i>	HR (95% CI)	<i>P</i>	
Grade (1 + 2 versus 3)							0.017
1 + 2	107 (52)	REF		104 (28)	REF		
3	62 (43)	2.64 (1.35–5.14)	0.005	58 (14)	0.79 (0.38–1.62)	0.52	
Dominant growth pattern							0.022
FEA/clinging/(micro)papillary	23 (7)	REF		23 (7)	REF		
Cribriform/solid	146 (88)	3.70 (1.34–10.23)	0.012	139 (35)	0.77 (0.32–1.85)	0.56	

n total number (number of patients with subsequent iIBC), *HR* Hazard Ratio, *CI* confidence interval, *P* *P* value, *REF* reference, *FEA* flat epithelial atypia

Fig. 3 Kaplan–Meier curve illustrating iIBC incidence after diagnosis of DCIS treated by BCS alone. *GP* growth pattern, *other* flat epithelial atypia, clinging and (micro)papillary growth pattern. The red dashed reference line depicts the maximum reached incidence in patients with DCIS grade 3 with a cribriform/solid growth pattern treated with BCS + RT



In univariable analysis, patients treated with radiotherapy after BCS had a strongly reduced risk of iIBC compared to those treated by BCS alone, as was already shown previously [30, 36, 37]. Also grade 3 (versus grade 1 + 2 combined), a high mitotic activity and a cribriform/solid growth pattern (versus FEA, clinging, or (micro)papillary growth pattern) were associated with increased iIBC risk in patients treated with BCS alone. In multivariable analysis however, only grade 3 (versus grade 1 + 2) and a cribriform/solid growth pattern were independently associated with an increased iIBC risk. Mitotic activity did not add any predictive value to grade 3 versus 1 + 2 and growth pattern in a multivariable model, though this is likely due to collinearity with grade. Another important finding in our study is that no histopathological features were associated with iIBC risk in the patients treated with BCS + RT. Although women in our study were not randomized for treatment arm, this finding may suggest that radiotherapy neutralizes the effect of these classical histopathological features. This is also in line with the fact that within the large randomized controlled trials

of RT in DCIS no subgroup could be identified without RT benefit [36].

So far, grade is the sole histopathological feature in DCIS that is used in clinical practice and also has an impact on eligibility in the context of clinical trials investigating the safety of active surveillance in low-risk DCIS [38–40]. In general, only women over the age of 45 or 50 with screen-detected calcifications associated with DCIS grade 1 or grade 2 are eligible in these trials. A three-tiered grading system is used for this selection purpose. Our study supports the rationale to distinguish between grade 1 + 2 versus grade 3 as DCIS grade 3 is independently associated with an increased risk of iIBC in patients treated with BCS alone. Unfortunately, the interrater reliability of assessing grade using either a 3-tiered grading system (grade 1, 2, or 3) or a 2-tiered system differentiating grade 1 + 2 combined versus grade 3 was only fair when considering KA and at best moderate based on the GAC2.

The interrater reliability for growth pattern was moderate (KA) to substantial (GAC2). The predictive ability of

grade and growth pattern has been intensively studied previously, with conflicting results [10]. Factors such as substantial interrater variability, grading system used, bias in designs, and relying on histopathological assessments of a single pathologist's opinion may have resulted in these different findings [10]. Interrater reliability based on GAC2 was higher overall, when histopathological features showed strongly skewed distribution and when agreement was already very high (i.e., grade 1 versus 2 + 3, growth pattern, and mitotic activity). Under these circumstances, a GAC2 test may result in more accurate reliability coefficients, as was previously shown in comparison with Cohen's kappa, which overestimates the concordance attributed due to chance alone in these situations leading to lower reliability coefficients [41].

In view of the prognostic value and interrater reliability observed in our study, it is questionable whether it is safe to base clinical treatment decisions solely on the assessment of classical histopathological features. Here, we propose four strategies that may improve risk stratification in DCIS.

Within the context of DCIS, the three features with reasonable prognostic value (grade 1 + 2 versus 3, growth pattern, and mitotic activity) are currently used in many grading systems, but without clear definitions and rules about how to value each feature. We therefore firstly would suggest to objectify histological grading by using a numerical semi-quantitative scoring system which separately evaluates each of these features, analogous to the modified Bloom and Richardson grading system for IBC [42, 43]. Dichotomous scoring systems may further improve reliability and prognostic value and should be further explored evaluating different cut-offs [44, 45].

Secondly, performing additional immunohistochemistry to assign specific DCIS profiles may add prognostic value, possibly only in subsets of patients (i.e., grade 2). Previously, associations were reported of human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-negative DCIS, and DCIS with high cyclooxygenase 2, p16, and Ki-67 levels with increased iIBC risk [9, 10, 46, 47]. These markers would be good candidates for further exploration. Automated scoring within this context may result in more standardized and objective assessment [48–51]. Previously, a 3-tiered grading system in DCIS, combining nuclear grade according to the Van Nuys criteria with automated Ki-67 count, was reported to show excellent correlation with immunohistochemical markers of reported biological relevance such as ER and HER2 [9, 46, 47, 50].

Thirdly, alternative approaches using pathology information such as artificial intelligence-based methods should also be considered in search for clinically relevant biomarkers in DCIS [52]. Recently, others have developed a whole slide image-based machine learning model, which accurately predicted the risk of an invasive or in situ recurrence and

significantly outperformed traditional clinicopathological variables [53].

Lastly, besides pathology, other criteria could also be incorporated in clinical decision schemes, e.g., as in current active surveillance trials requiring DCIS to be screen-detected based on calcifications only without clinical symptoms and diagnosed on representative vacuum-assisted biopsies [38–40].

Our study had several limitations. From our study population, each rater scored a different subset of patients. Therefore, we were not able to analyze the association of histopathological DCIS features with iIBC risk per rater or grading system used and to study the effect of interrater variability on risk stratification. However, the resulting immense workload would probably have caused major rater-dropout. Also tissue slides were digitally assessed using research technology producing images of somewhat lower resolution. This may have led to difficulty of assessing histopathological features requiring great detail, such as mitotic activity. Our reliability study was nonetheless performed under conditions as close as possible to clinical practice, as a large set of non-selected DCIS cases from a population-based cohort were reviewed by a large group of raters with varying levels of expertise without provision of instructions or tutorials beforehand. And lastly, data on margin status and DCIS lesion size, factors potentially associated with the risk of iIBC, were not collected in a standardized way [10, 46, 47, 54]. However, Dutch guidelines state that a re-excision or mastectomy is obligatory in case of involved margins after a primary excision. An explorative analysis using the available data on margin status indeed showed no significant difference in the risk of iIBC for positive margins and even a protective effect for close margins in women treated with BCS alone in comparison to women with negative margins, suggesting they were subjected to re-excisions.

Conclusions

We evaluated the prognostic value of histopathological DCIS features to inform risk stratification using a unique, combined approach. Our study showed substantial interrater variability in the classification of histopathological DCIS features, while using rater majority opinions, minimizing the muddling effect of interrater variability, DCIS grade, growth pattern, and mitotic activity were associated with the risk of subsequent ipsilateral invasive breast cancer after DCIS in patients treated with BCS without radiotherapy. A semi-quantitative grading system incorporating and separately evaluating nuclear pleomorphism, growth pattern, and mitotic activity, analogue to IBC grading, may improve the reliability and prognostic value of these histopathological features.

Acknowledgements The authors thank all collaborating hospitals and PALGA, the nationwide network and registry of histo- and cytopathology, for facilitating retrieval of archival tissue material and providing pathology data. The authors thank the Netherlands Comprehensive Cancer Organization for providing data of the Netherlands Cancer Registry. The authors would like to thank the Dutch screening organization for providing screening data. The authors would like to acknowledge the NKI- AVL Core Facility Molecular Pathology & Biobanking (CFMPB) for supplying lab support. We thank all other pathologists who participated in the study: Mariëtte Giessen, Erik Nijhuis, Erwin Geuken, Frank Bellot, Karen Koopman, Ivana Verlinden, Mariël Brinkhuis, Franka van Merriënboer, Gesina van Lijnschoten, Horst Bürger, Alicia Córdoba, Inta Liepniece-Karele, and Grace Callagy.

Author contributions EJG, EHL, MS, and JW were responsible for the study design. EJG coordinated the study. LM provided technical support. EJG revised all slides. JH provided an online platform to enable pathology scoring. MvS, MMA, SA, AK, AR, ZV, FJAN, SB, WV, EB, MVB, JK, EC, EB, MJdR, WV, AF, NELF, PR, PJW, LFSK, CQ, GF, GS, and PJvD scored the slides for the reliability study. EJG analyzed the data under supervision of MS. EJG wrote the manuscript with significant contributions by all authors. All authors read and approved the final manuscript.

Funding This work was supported by KWF Kankerbestrijding (Grant Number NKI2014-7167) and by Cancer Research UK and by KWF Kankerbestrijding in a joint grant (Grant Number C38317/A24043).

Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. Requests should be made to Prof. J. Wesseling: j.wesseling@nki.nl.

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflicts of interest.

Ethics approval This retrospective study involving human participants was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the review boards of the NKI-AVL, the Netherlands Cancer Registry, the nationwide network and registry of histology and cytopathology in the Netherlands and the Dutch breast cancer screening organization.

Informed consent The study used only unidentifiable patient information, and no informed consent was required.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Virnig BA, Tuttle TM, Shamlivan T, Kane RL (2010) Ductal carcinoma in Situ of the breast: A systematic review of incidence, treatment, and outcomes. *J Natl Cancer Inst.* 102(3):170–178
2. Netherlands Comprehensive Cancer Organisation (IKNL). Available from: <https://www.cijfersoverkanker.nl>
3. Cancer Research UK. Available from: <https://www.cancerresearchuk.org/>
4. Ripping TM, Verbeek ALM, Fracheboud J, De Koning HJ, Van Ravesteyn NT, Broeders MJM (2015) Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in the Netherlands. *Int J Cancer.* 137(4):921–929
5. Harding C, Pompei F, Burmistrov D, Welch HG, Abebe R, Wilson R (2015) Breast cancer screening, incidence, and mortality across US counties. *JAMA Intern Med.* 175(9):1483–1489
6. van Luijt PA, Heijnsdijk EAM, Fracheboud J, Overbeek LIH, Broeders MJM, Wesseling J et al (2016) The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. *Breast Cancer Res.* 18(1):47
7. Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. *Breast Cancer Res Treat* 97(2):135–144
8. Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R et al (2019) Cancer outcomes in DCIS patients without locoregional treatment. *J Natl Cancer Inst* 111(9):952–960
9. Lari SA, Kuerer HM (2011) Biological markers in DCIS and risk of breast recurrence: a systematic review. *J Cancer.* 2:232
10. Visser LL, Groen EJ, Van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J (2019) Predictors of an invasive breast cancer recurrence after DCIS: A Systematic Review and Meta-analyses. *Cancer Epidemiol Biomark Prev* 28(5):835–845
11. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, Van de Vijver MJ et al (1994) Ductal carcinoma in situ: a proposal for a new classification. *Semin Diagn Pathol* 11(3):167–180
12. Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H et al (2010) A new pathological system for grading DCIS with improved prediction of local recurrence: Results from the UKCCCR/ANZ DCIS trial. *Br J Cancer.* 103(1):94–100
13. Cserni G, Sejbien A (2019) Grading Ductal Carcinoma In Situ (DCIS) of the breast – what's wrong with It? *Pathol Oncol Res* 26(2):665–671. <https://doi.org/10.1007/s12253-019-00760-8>
14. Lagios MD (1990) Duct carcinoma in situ. *Pathology and treatment.* *Surg Clin North Am.* 70(4):873–883
15. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED et al (1995) Prognostic classification of breast ductal carcinoma-in-situ. *Lancet* 345(8958):1154–1157
16. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W et al (1998) Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. *European Commission Working Group on Breast Screening Pathology.* *Hum Pathol* 29(10):1056–1062
17. Wells WA, Carney PA, Eliassen MS, Grove MR, Tosteson ANA (2000) Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. *Am J Surg Pathol* 24(5):651–659
18. Bethwaite P, Smith N, Delahunt B, Kenwright D (1998) Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. *J Clin Pathol* 51:450–454
19. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO classification of tumours of the breast, 4th edn. International Agency for Research on Cancer, Lyon
20. College of American pathologists. Available from: <https://documents.cap.org/protocols/cp-breast-dcis-18protocol-4100.pdf>

21. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blamey RW et al (1994) Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. *Mod Pathol* 7(2):257–262
22. Elston CW, Sloane JP, Amendeira I, Apostolikas N, Bellocq JP, Bianchi S et al (2000) Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. *Eur J Cancer* 36(14):1769–1772
23. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL (1997) Ductal carcinoma in situ of the breast: Reproducibility of histological subtype analysis. *Hum Pathol* 28(8):967–973
24. Schuh F, Biazús JV, Resetkova E, Benficia CZ, Edelweiss MIA (2010) Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey. *Pathol Res Pract* 206(10):705–711
25. Schuh F, Biazús JV, Resetkova E, Benficia CZ, Ventura A, de Freitas Uchoa D et al (2015) Histopathological grading of breast ductal carcinoma in situ: validation of a web-based survey through intra-observer reproducibility analysis. *Diagn Pathol* 10(1):93
26. Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA et al (2015) Diagnostic concordance among pathologists interpreting breast biopsy specimens. *JAMA* 313(11):1122–1132
27. Verkooijen HM, Peterse JL, Schipper MEI, Buskens E, Hendriks JHCL, Pijnappel RM et al (2003) Interobserver variability between general and expert pathologists during the histopathological assessment of large-core needle and open biopsies of non-palpable breast lesions. *Eur J Cancer*. 39(15):2187–2191
28. van Dooijeweert C, van Diest PJ, Willems SM, Kuijpers CCHJ, Overbeek LIH, Deckers IAG (2019) Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. *Breast Cancer Res Treat*. 174(2):479–488. <https://doi.org/10.1007/s10549-018-05082-y>
29. Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A et al (2011) Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. *Int J Nurs Stud*. 48(6):661–671
30. Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J (2016) Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. *Breast Cancer Res Treat* 159(3):553–563
31. Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Van De Pol A, Van Krieken JHJM et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Cell Oncol* 29(1):19–24
32. Barlow WE, Ichikawa L, Rosner D, Izumi S (1999) Analysis of case-cohort designs. *J Clin Epidemiol* 52(12):1165–1172
33. Hayes AF, Krippendorff K (2007) Answering the call for a standard reliability measure for coding data. *Commun Methods Meas* 1(1):77–89
34. Gwet KL (2014) Handbook of inter-rater reliability: the definitive guide to measuring the extent of agreement among raters, 4th edn. Advanced Analytics, LLC, Gaithersburg
35. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. *Biometrics* 33(1):159–174
36. Correa C, McGale P, Taylor C, Davidson N, Gelber R, Piccart M et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst* 41(41):162–177
37. Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. *J Clin Oncol* 31(32):4054–4059
38. Elshof LE, Tryfonidis K, Slaets L, Van Leeuwen-Stok AE, Skinner VP, Dif N et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ: The LORD study. *Eur J Cancer* 51(12):1497–1510
39. Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JMS, Brookes C et al (2015) Addressing overtreatment of screen detected DCIS. The LORIS trial. *Eur J Cancer* 51(16):2296–2303
40. Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D et al (2019) The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). *BMJ Open* 9(3):e026797
41. Gwet KL (2008) Computing inter-rater reliability and its variance in the presence of high agreement. *Br J Math Stat Psychol* 61(1):29–48
42. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer a study of 1409 cases of which 359 have been followed for 15 years. *Br J Cancer* 11(3):359–377
43. Elston CW, Ellis IO (1991) The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 19(5):403–410
44. Van Bockstal M, Baldewijns M, Colpaert C, Dano H, Floris G, Galant C et al (2018) Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial inter-observer concordance. *Histopathology* 73(6):923–932
45. Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F et al (2019) Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. *Mod Pathol* 33(3):354–366
46. Visser LL, Elshof LE, Schaapveld M, Van De Vijver K, Groen EJ, Almekinders MM et al (2018) Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ—a nested case-control study. *Clin Cancer Res* 24(15):3593–3601
47. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. *J Natl Cancer Inst* 102(9):627–637
48. Mohammed ZMA, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E et al (2012) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. *Br J Cancer* 106(2):383–388
49. Van Velthuysen MLF, Groen EJ, Sanders J, Prins FA, Van Der Noort V, Korse CM (2014) Reliability of proliferation assessment by Ki-67 expression in neuroendocrine neoplasms: eyeballing or image analysis? *Neuroendocrinology* 100(4):288–292
50. Stasik CJ, Davis M, Kimler BF, Fan F, Damjanov I, Thomas P et al (2011) Grading ductal carcinoma in situ of the breast using an automated proliferation index. *Ann Clin Lab Sci* 41(2):122–130
51. Balkenhol MCA, Tellez D, Vreuls W, Clahsen PC, Pinckaers H, Ciompi F et al (2019) Deep learning assisted mitotic counting for breast cancer. *Lab Invest* 99(11):1596–1606. <https://doi.org/10.1038/s41374-019-0275-0>
52. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A (2019) Artificial intelligence in digital pathology: new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol* 16(11):703–715. <https://doi.org/10.1038/s41571-019-0252-y>
53. Klimov S, Miligiy IM, Gertych A, Jiang Y, Toss MS, Rida P et al (2019) A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. *Breast Cancer Res* 21(1):1–19

54. Collins LC, Achacoso N, Haque R, Nekhlyudov L, Fletcher SW, Quesenberry CP et al (2013) Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. *Breast Cancer Res Treat* 139(2):453–460

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Emma J. Groen¹ · Jan Hudecek² · Lennart Mulder³ · Maartje van Seijen³ · Mathilde M. Almekinders³ · Stoyan Alexov⁴ · Anikó Kovács⁵ · Ales Ryska⁶ · Zsuzsanna Varga⁷ · Francisco-Javier Andreu Navarro⁸ · Simonetta Bianchi⁹ · Willem Vreuls¹⁰ · Eva Balslev¹¹ · Max V. Boot¹² · Janina Kulka¹³ · Ewa Chmielik¹⁴ · Ellis Barbé¹² · Mathilda J. de Rooij¹⁵ · Winand Vos¹⁶ · Andrea Farkas¹⁷ · Natalja E. Leeuwis-Fedorovich¹⁸ · Peter Regitnig¹⁹ · Pieter J. Westenend²⁰ · Loes F. S. Kooreman²¹ · Cecily Quinn²² · Giuseppe Floris^{23,24} · Gábor Cserni^{25,26} · Paul J. van Diest²⁷ · Esther H. Lips³ · Michael Schaapveld²⁸ · Jelle Wesseling^{1,3}  on behalf of Grand Challenge PRECISION consortium

Grand Challenge PRECISION consortium
precision@nki.nl

- 1 Department of Pathology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
- 2 Department of Research IT, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- 3 Department of Molecular Pathology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- 4 Department of Pathology, Oncology Hospital, Sofia, Bulgaria
- 5 Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
- 6 The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 7 Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
- 8 Atryshealth Co, S.L., Barcelona, Spain
- 9 Division of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy
- 10 Department of Pathology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
- 11 Department of Pathology, Herlev University Hospital, Herlev, Denmark
- 12 Department of Pathology, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands
- 13 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
- 14 Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
- 15 Symbiant Pathology Expert Centre, Location ZMC, Zaandam, The Netherlands
- 16 Department of Pathology, Zuyderland Medical Center, Location Sittard-Geleen, Sittard-Geleen, The Netherlands
- 17 Department of Pathology, Gävle Hospital, Gävle, Sweden
- 18 Department of Pathology, Deventer Hospital, Deventer, The Netherlands
- 19 Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
- 20 Laboratory for Pathology Dordrecht, Dordrecht, The Netherlands
- 21 Department of Pathology and GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
- 22 Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital, Dublin, Ireland
- 23 Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, KU Leuven - University of Leuven, Leuven, Belgium
- 24 Department of Pathology, University Hospitals Leuven, Leuven, Belgium
- 25 Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary
- 26 Department of Pathology, University of Szeged, Szeged, Hungary
- 27 Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- 28 Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands